A recent study published in Future Oncology has revealed the symptoms and impacts of living with metastatic castration-resistant prostate cancer (mCRPC). The qualitative research study in Japan investigated patient’s experience with mCRPC from their diagnosis to the decision for RA-233 treatment.
This video describes the symptoms and impacts that mCRPC patients experience from diagnosis to experiencing bone metastasis. It shows how important it is for patient to talk about their symptoms with their physicians.
Read the original article:
A qualitative research study in Japan investigating patients’ experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K, Uemura H, Miyazaki K et al.
Future Oncology 17(36), 5103-5118 (2021) DOI: 10.2217/fon-2021-0773